+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tumor-Infiltrating Lymphocyte Therapy Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Tumor-Infiltrating Lymphocyte Therapy Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Tumor-Infiltrating Lymphocyte Therapy Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6081124
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The advent of tumor-infiltrating lymphocyte (TIL) therapy marks a pivotal moment in oncology, offering a personalized immunotherapeutic approach that harnesses the patient’s own immune cells to target and eradicate malignant tumors. By isolating lymphocytes from a patient’s tumor, expanding and activating them ex vivo, and reinfusing them, this modality has demonstrated durable responses in several refractory solid tumors. Initial clinical successes in melanoma laid the groundwork for broader applications across diverse cancer types, fueling academic and commercial interest worldwide. As research accelerates, key stakeholders-ranging from academic institutions to biopharma innovators-are intensifying efforts to refine manufacturing processes, enhance cell persistence, and optimize safety profiles. With regulatory agencies acknowledging the promise of adoptive cell therapies, TIL is poised to transition from niche investigational use to a standard-of-care component in oncology. This introduction sets the stage for an in-depth exploration of the transformative shifts redefining TIL therapy, the impact of evolving trade policies, segmentation insights, regional dynamics, and strategic recommendations for industry leaders.

Transformative Technological and Clinical Shifts in the TIL Landscape

Over the past decade, TIL therapy has undergone transformative shifts fueled by technological breakthroughs and clinical validation. Innovations in gene modification techniques, such as CRISPR and CAR-T integrations, have enhanced lymphocyte targeting and persistence. Concurrently, the evolution from traditional two-dimensional culture systems to three-dimensional hydrogel and microcarrier platforms has improved expansion yields and functional phenotypes. The integration of rapid expansion protocols has shortened manufacturing timelines, while novel slow expansion regimens preserve memory-like TIL subsets that confer long-term tumor surveillance. In parallel, academic-industry partnerships have streamlined translational pipelines, facilitating multicenter clinical trials across melanoma, lung, colorectal, and renal cell carcinomas. Regulatory frameworks have adapted, granting breakthrough and regenerative medicine designations that accelerate approval pathways. These shifts collectively underpin a paradigm where personalized cell therapies graduate from proof-of-concept studies to scalable treatment options, reshaping clinical strategies and investment priorities across the oncology landscape.

Cumulative Impact of United States Tariffs Introduced in 2025

The introduction of new U.S. tariffs in 2025 presents multifaceted challenges for TIL therapy development and commercialization. Increased duties on imported bioreactor components, specialized reagents, and single-use consumables will elevate production costs at manufacturing sites reliant on global supply chains. Companies that source microcarrier beads, hydrogel matrices, and gene editing kits from overseas suppliers may experience margin compression and logistical delays. In response, stakeholders are exploring reshoring strategies and local vendor development to mitigate tariff-induced cost inflation. At the same time, higher material costs risk constraining access in research settings, potentially delaying preclinical programs and multicenter trials. However, these pressures also incentivize process optimization-driving adoption of closed-system bioreactors, reduced reagent consumption protocols, and in-house reagent synthesis. Regulatory bodies are monitoring these dynamics to ensure patient access remains unimpeded. Ultimately, while the 2025 tariff landscape imposes notable headwinds, it also catalyzes innovation in manufacturing resilience and supply chain diversification.

Key Segmentation Insights Across Applications and Technologies

Segmentation analysis reveals critical insights into areas of unmet need and high-growth potential. When evaluated across therapeutic applications-ranging from melanoma to colorectal and cervical cancers-TIL therapy achieves its most robust clinical responses in melanoma, yet emerging evidence shows promising antitumor activity in lung and breast cancer cohorts. Examining cell source origin, allogeneic lymphocyte platforms offer scalability advantages but face immune rejection risks, while autologous and peripheral blood-derived lymphocytes balance safety and efficacy with individualized manufacturing demands. A deeper dive into manufacturing technologies highlights that two-dimensional culture systems remain standard for early-phase trials, whereas three-dimensional hydrogel and microcarrier systems substantially enhance cell yields; rapid expansion protocols accelerate time to infusion, and gene modification through CAR-T, CRISPR, and TALEN platforms deepens mechanistic versatility. Patient demographic segmentation underscores that elderly and middle-aged adult populations represent the bulk of clinical trial enrollees, yet pediatric and young adult cohorts warrant tailored protocols given distinct tumor microenvironments. Differentiating monotherapy versus combination approaches-particularly with chemotherapy or radiation-clarifies synergy patterns. End users span cancer research institutes, hospitals, and specialty clinics, while development stage split between preclinical and clinical trials indicates a rich pipeline. Mechanism of action categories-cytotoxicity, immune modulation, lymphokine-activated killing-as well as safety and efficacy measures anchored in adverse effects and therapeutic index, collectively guide clinical strategy and risk management.

Key Regional Insights in the Global TIL Therapy Market

Regional dynamics significantly shape the trajectory of TIL therapy adoption and commercialization. In the Americas, robust venture capital inflows and leading academic centers drive a high volume of clinical trials, while regulatory agencies have established clear pathways for breakthrough and regenerative medicine designations. Europe, the Middle East & Africa benefit from pan-regional consortia and shared manufacturing infrastructures that streamline multicountry studies, though reimbursement frameworks vary widely, influencing market entry timelines. The Asia-Pacific region exhibits rapid capacity expansion, with government-led initiatives promoting domestic biomanufacturing and intellectual property incentives; collaborations between local biotech hubs and multinational firms accelerate technology transfer, yet logistical and regulatory heterogeneity across countries necessitate agile market approaches. These regional distinctions inform strategic site selection for clinical development, facility placement, and partnership formations, ensuring companies align resources with the most favorable regulatory and economic environments.

Insights into Leading Companies Steering TIL Therapy Innovation

Leading companies are positioning themselves through differentiated portfolios and strategic collaborations. Achilles Therapeutics plc is pioneering neoantigen-targeted TIL therapies, leveraging proprietary predictive algorithms. Adaptimmune Therapeutics plc combines TIL with T-cell receptor engineering to enhance tumor specificity. Autolus Therapeutics plc focuses on next-generation gene-editing modalities that refine lymphocyte function. BrightPath Biotherapeutics Co., Ltd. integrates scalable microcarrier-based culture systems to boost yields, while Celyad Oncology SA emphasizes allogeneic off-the-shelf TIL products. Immatics N.V. employs proprietary epitope discovery platforms to accelerate candidate identification, and Instil Bio, Inc. champions memory-like TIL subsets for sustained responses. Iovance Biotherapeutics, Inc. leads late-stage melanoma trials, Kite Pharma, a Gilead Company, expands manufacturing capacity for TIL across multiple indications, and Lion TCR Pte. Ltd. develops novel TCR fusion constructs. Lytix Biopharma AS integrates immunomodulatory adjuvants to potentiate TIL activity, whereas Marker Therapeutics, Inc. refines patient selection through biomarker-driven protocols. Medigene AG focuses on modular TCR integration, Precision Biosciences, Inc. advances CRISPR-based genome editing, and Tessa Therapeutics Pte. Ltd. pioneers off-the-shelf allogeneic approaches. Collectively, these leaders shape competitive dynamics through innovation, scale-up partnerships, and clinical pipeline breadth.

Actionable Recommendations for Industry Leaders to Drive Growth

Industry stakeholders can capitalize on emerging opportunities by aligning strategic priorities with market dynamics. First, invest in modular and closed-system manufacturing platforms to reduce dependency on imported consumables and mitigate tariff exposures. Second, pursue diversified cell sourcing strategies-balancing allogeneic scalability with the safety profile of autologous and peripheral blood lymphocytes-to tailor offerings across patient segments. Third, integrate gene modification advances, such as CRISPR-based checkpoint editing, to enhance TIL potency and broaden indications beyond melanoma. Fourth, establish regional manufacturing hubs in strategic geographies to navigate heterogeneous regulatory landscapes and secure favorable reimbursement pathways. Fifth, deepen collaborations with academic consortia and contract development organizations to accelerate trial enrollment and expand access. Sixth, implement adaptive clinical trial designs that leverage real-world evidence and biomarker-driven patient stratification to demonstrate safety and efficacy more efficiently. Lastly, strengthen post-infusion patient monitoring frameworks to proactively manage adverse events and optimize therapeutic index, thereby reinforcing payer confidence.

Conclusion: Navigating the Path to TIL Therapy Commercialization

Tumor-infiltrating lymphocyte therapy stands at the cusp of mainstream adoption, propelled by technological ingenuity, collaborative ecosystems, and evolving regulatory support. Transformative shifts in culture systems, gene editing, and expansion protocols have expanded the scope of indications and improved response durability. Although U.S. tariffs introduce new cost considerations, they simultaneously encourage supply chain optimization and local manufacturing investments. Segmentation insights clarify priority applications, cell sources, and patient subgroups, while regional analysis guides resource allocation and partnership strategies. Leading companies are differentiating through proprietary platforms and strategic alliances, underscoring the vitality of innovation ecosystems. By executing targeted recommendations-ranging from advanced manufacturing investments to adaptive trial designs-stakeholders can navigate challenges and unlock the full therapeutic and commercial potential of TIL therapy. As the field matures, sustained collaboration across industry, regulators, and clinical institutions will be instrumental in delivering transformative treatments to patients worldwide.

Market Segmentation & Coverage

This research report categorizes the Tumor-Infiltrating Lymphocyte Therapy Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Melanoma
  • Renal Cell Carcinoma
  • Allogeneic Tumor-Infiltrating Lymphocytes
  • Autologous Tumor-Infiltrating Lymphocytes
  • Peripheral Blood Lymphocytes
  • Cell Culture Techniques
    • 2D Culture Systems
    • 3D Culture Systems
      • Hydrogel Systems
      • Microcarrier Systems
  • Expansion Techniques
    • Rapid Expansion Protocols
    • Slow Expansion Protocols
  • Gene Modification Techniques
    • CAR-T
    • CRISPR
    • TALEN
  • Adult
    • Elderly
    • Middle-Aged Adults
    • Young Adults
  • Pediatric
  • Combination Therapy
    • With Chemotherapy
    • With Radiation Therapy
  • Monotherapy
  • Cancer Research Institutes
  • Hospitals
  • Specialty Clinics
  • Clinical Trials
  • Preclinical
  • Cytotoxicity
  • Immune Modulation
  • Lymphokine-Activated Killing
  • Adverse Effects
  • Therapeutic Index

This research report categorizes the Tumor-Infiltrating Lymphocyte Therapy Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Tumor-Infiltrating Lymphocyte Therapy Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Achilles Therapeutics plc
  • Adaptimmune Therapeutics plc
  • Autolus Therapeutics plc
  • BrightPath Biotherapeutics Co., Ltd.
  • Celyad Oncology SA
  • Immatics N.V.
  • Instil Bio, Inc.
  • Iovance Biotherapeutics, Inc.
  • Kite Pharma, a Gilead Company
  • Lion TCR Pte. Ltd.
  • Lytix Biopharma AS
  • Marker Therapeutics, Inc.
  • Medigene AG
  • Precision Biosciences, Inc.
  • Tessa Therapeutics Pte. Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tumor-Infiltrating Lymphocyte Therapy Market, by Therapeutic Applications
8.1. Introduction
8.2. Breast Cancer
8.3. Cervical Cancer
8.4. Colorectal Cancer
8.5. Lung Cancer
8.6. Melanoma
8.7. Renal Cell Carcinoma
9. Tumor-Infiltrating Lymphocyte Therapy Market, by Cell Source Origin
9.1. Introduction
9.2. Allogeneic Tumor-Infiltrating Lymphocytes
9.3. Autologous Tumor-Infiltrating Lymphocytes
9.4. Peripheral Blood Lymphocytes
10. Tumor-Infiltrating Lymphocyte Therapy Market, by Manufacturing Technology
10.1. Introduction
10.2. Cell Culture Techniques
10.2.1. 2D Culture Systems
10.2.2. 3D Culture Systems
10.2.2.1. Hydrogel Systems
10.2.2.2. Microcarrier Systems
10.3. Expansion Techniques
10.3.1. Rapid Expansion Protocols
10.3.2. Slow Expansion Protocols
10.4. Gene Modification Techniques
10.4.1. CAR-T
10.4.2. CRISPR
10.4.3. TALEN
11. Tumor-Infiltrating Lymphocyte Therapy Market, by Patient Demographics
11.1. Introduction
11.2. Adult
11.2.1. Elderly
11.2.2. Middle-Aged Adults
11.2.3. Young Adults
11.3. Pediatric
12. Tumor-Infiltrating Lymphocyte Therapy Market, by Type Of Therapy
12.1. Introduction
12.2. Combination Therapy
12.2.1. With Chemotherapy
12.2.2. With Radiation Therapy
12.3. Monotherapy
13. Tumor-Infiltrating Lymphocyte Therapy Market, by End-User
13.1. Introduction
13.2. Cancer Research Institutes
13.3. Hospitals
13.4. Specialty Clinics
14. Tumor-Infiltrating Lymphocyte Therapy Market, by Development Stage
14.1. Introduction
14.2. Clinical Trials
14.3. Preclinical
15. Tumor-Infiltrating Lymphocyte Therapy Market, by Mechanism Of Action
15.1. Introduction
15.2. Cytotoxicity
15.3. Immune Modulation
15.4. Lymphokine-Activated Killing
16. Tumor-Infiltrating Lymphocyte Therapy Market, by Safety And Efficacy Measures
16.1. Introduction
16.2. Adverse Effects
16.3. Therapeutic Index
17. Americas Tumor-Infiltrating Lymphocyte Therapy Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Tumor-Infiltrating Lymphocyte Therapy Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Achilles Therapeutics plc
20.3.2. Adaptimmune Therapeutics plc
20.3.3. Autolus Therapeutics plc
20.3.4. BrightPath Biotherapeutics Co., Ltd.
20.3.5. Celyad Oncology SA
20.3.6. Immatics N.V.
20.3.7. Instil Bio, Inc.
20.3.8. Iovance Biotherapeutics, Inc.
20.3.9. Kite Pharma, a Gilead Company
20.3.10. Lion TCR Pte. Ltd.
20.3.11. Lytix Biopharma AS
20.3.12. Marker Therapeutics, Inc.
20.3.13. Medigene AG
20.3.14. Precision Biosciences, Inc.
20.3.15. Tessa Therapeutics Pte. Ltd.
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET MULTI-CURRENCY
FIGURE 2. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 22. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2024 VS 2030 (%)
FIGURE 24. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ALLOGENEIC TUMOR-INFILTRATING LYMPHOCYTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PERIPHERAL BLOOD LYMPHOCYTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HYDROGEL SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MICROCARRIER SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RAPID EXPANSION PROTOCOLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SLOW EXPANSION PROTOCOLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CAR-T, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CRISPR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TALEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY WITH RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CYTOTOXICITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY IMMUNE MODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LYMPHOKINE-ACTIVATED KILLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADVERSE EFFECTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC INDEX, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 107. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 108. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 109. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 111. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 112. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 113. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 114. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 115. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 116. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 117. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 118. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 120. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 121. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 122. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 124. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 126. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 128. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 129. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 131. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 132. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 133. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 135. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 136. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 184. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 185. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 186. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 188. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 189. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 190. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 191. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 192. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 193. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 194. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 195. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 197. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 198. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 199. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 200. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 201. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 202. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 203. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 204. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 205. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 206. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 207. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 208. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 209. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 210. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 212. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 213. INDIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 216. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 219. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 229. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 230. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 231. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 233. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 234. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 235. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 236. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 237. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 238. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 239. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 240. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 242. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 243. JAPAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 244. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 245. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 246. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 247. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 248. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 249. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 250. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 252. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL CULTURE TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 263. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY 3D CULTURE SYSTEMS, 2018-2030 (USD MILLION)
TABLE 264. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY EXPANSION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 265. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GENE MODIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 267. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 268. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 270. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 272. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 273. PHILIPPINES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SAFETY AND EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 274. SINGAPORE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 275. SINGAPORE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE ORIGIN, 2018-2030 (USD MILLION)
TABLE 276. SINGAPORE TUMOR-INFILTRATING LYMPHOCYTE TH

Companies Mentioned

  • Achilles Therapeutics plc
  • Adaptimmune Therapeutics plc
  • Autolus Therapeutics plc
  • BrightPath Biotherapeutics Co., Ltd.
  • Celyad Oncology SA
  • Immatics N.V.
  • Instil Bio, Inc.
  • Iovance Biotherapeutics, Inc.
  • Kite Pharma, a Gilead Company
  • Lion TCR Pte. Ltd.
  • Lytix Biopharma AS
  • Marker Therapeutics, Inc.
  • Medigene AG
  • Precision Biosciences, Inc.
  • Tessa Therapeutics Pte. Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Tumor-Infiltrating Lymphocytes - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Tumor-Infiltrating Lymphocytes - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Tumor Infiltrating Lymphocytes Market Report 2025 - Product Image

Tumor Infiltrating Lymphocytes Market Report 2025

  • Report
  • 200 Pages
  • Global
From
TIL Therapy - Pipeline Insight, 2025 - Product Image

TIL Therapy - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Cellular Immunotherapy Market Report 2025 - Product Image

Cellular Immunotherapy Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Targeted Therapy Drugs for Melanoma Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Targeted Therapy Drugs for Melanoma Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global, United States Global, United States
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.